15 September 2017 - 15 September 2017 – LexaGene announces, as per reporting requirements, the voting results for election of its Board of Directors at the recent Annual General Meeting. VIEW RELEASE > VIEW

15 August 2017 - 15 August 2017 – LexaGene announces the appointment of Manohar Furtado, Ph.D., to the Company’s Board of Directors. Dr. Furtado has extensive experience working in the life sciences industry for over 30 years. VIEW RELEASE > VIEW

6 July 2017 - 6 July 2017 – LexaGene is pleased to report that the technology for its automated pathogen detection instrument has been successfully de-risked through a series of tests, and an unveiling scheduled. VIEW RELEASE > VIEW

3 May 2017 - LexaGene is pleased to report that the development of the alpha prototype remains on track and is scheduled to be completed by the end of this November 2017. VIEW RELEASE > VIEW

21 March 2017 - LexaGene is pleased to announce that DMG Productions has selected LexaGene to be featured in an upcoming episode of Innovations with Ed Begley Jr. The show will air in the third quarter of 2017 on the FOX Business Network, which is viewed by approximately 85 million households worldwide. As a benefit of being selected, DMG […] > VIEW

13 March 2017 - LexaGene is pleased to announce that further to its news release of February 10, 2017 the Company closed its non-brokered private placement (the “Offering”) with the sale of 6,685,363 units at $0.30 per unit for gross proceeds of $2,005,609. > VIEW RELEASE > VIEW

9 March 2017 - LexaGene is pleased to announce that the Company has started trading on the OTCQB Venture Market in the United States under the symbol LXXGF. The OTCQB is equivalent in Canada to the TSX Venture Exchange for early-stage and developing companies. VIEW RELEASE > VIEW

6 March 2017 - LexaGene is pleased to announce that it has received conditional approval from the TSX Venture Exchange (the “Exchange”) to close its previously announced non-brokered private placement (the “Offering”) with the sale of a maximum of 6,700,000 units (the “Units”) at $0.30 per Unit for gross proceeds of $2,010,000. VIEW RELEASE   > VIEW

3 March 2017 - LexaGene announces that it has granted to directors and officers of the Company stock options (the “Options” to purchase a total of 1,675,000 common shares at a price of $0.33 per common share, and 500,000 common shares at a price of $0.363 per common share. VIEW RELEASE > VIEW

10 February 2017 - LexaGene is pleased to announce it intends to complete a non-brokered private placement to raise up to $2,010,000 by the issuance of 6,700,000 units at $0.30 per unit.   Each unit will consist of one common share and one common share purchase warrant.  Each warrant will entitle the holder to acquire an additional common share for […] > VIEW